A Phase 3 interventional study of Placebo and TAK-438 10 mg in Non-erosive Gastroesophageal Reflux Disease, sponsored by Takeda. Completed at 30 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-08-02.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing vonoprazan in Gastroesophageal Reflux — 5 open to participants now, 5 under way, 1 of them phase 3. vonoprazan · Gastroesophageal Reflux.
Among the 16 studies testing vonoprazan in Gastroesophageal Reflux, this one is the 4th largest by enrollment, is the only one that started in 2016, is one of 3 in phase 3, and was the 3rd registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
Browse Gastroesophageal Reflux studies →5 of the 16 studies testing vonoprazan in Gastroesophageal Reflux are open now, in 4 countries. Recruiting first, the newest first:
Phathom Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Asian Institute of Gastroenterology, India · Sites in India
Ages 18–75
Asian Institute of Gastroenterology, India · Sites in India
Ages 18–75
Tanta University · Sites in Egypt
Ages 17–60
Fu Jen Catholic University Hospital · Sites in Taiwan
Ages 20–75
By country, each count listing its studies:
vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →
Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 484 is above the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 118 across the 16 interventional studies. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 16 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
41 studies in Gastroesophageal Reflux by Takeda: none open now, none under way, none of them phase 3. Of 39 finished, 22 (56%) have results posted.
Among the 41 studies in Gastroesophageal Reflux by Takeda, this one is the 13th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2016, is one of 16 in phase 3, and was the 40th registered.
Takeda’s Gastroesophageal Reflux studies by the year they started, since 2000.
2 of the studies testing vonoprazan in Gastroesophageal Reflux that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07752407Phase 3Phathom Pharmaceuticals, Inc.A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks | 2027-10-20 |
| NCT06953986Asian Institute of Gastroenterology, IndiaA Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks | 2026-11-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies testing vonoprazan in Gastroesophageal Reflux, from their registry updates:
Among Takeda’s 41 in Gastroesophageal Reflux:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the efficacy and safety of oral TAK-438 10 mg once-daily in the treatment of non-erosive gastroesophageal reflux disease (NERD).
A phase 3, randomized, double-blind, placebo-controlled, parallel-group, multi-center study will be conducted to verify the superiority of TAK-438 (TAK-438 10 mg, once daily, 4 weeks) to placebo (placebo, once daily, 4 weeks) in participants with non-erosive gastroesophageal reflux disease (NERD).
The study consists of a 1-week, single-blind run-in period and a 4-week, double-blind treatment period. The participants will receive the study drug (TAK-438 placebo tablet) for the 1-week single-blind run-in period. After the run-in period, eligible participants will be randomized into TAK-438 10 mg or placebo treatment groups in a 1:1 ratio. The randomized participants will receive the assigned study drug (TAK-438 10 mg tablet or placebo tablet) for the 4-week double-blind treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The participant is endoscopically confirmed to have the modified Los Angeles (LA) Classification Grade N or M at the start of the run-in period (Visit 1).
To allow efficacy evaluation in the participants with Grade N as well as in those with Grade M, the target number of participants in each grade is at least 30% of the total number of participants. Enrollment of patients with either Grade N or M will end when the number of enrolled participants with each grade exceeds 332, or 70% of the total planned number of participants.
Exclusion Criteria:
The participant has any of the following abnormal clinical laboratory test values at the start of the run-in period (Visit 1):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-438 placebo-matching tablets, orally, once daily after breakfast for 1 week in run-in period followed by TAK-438 placebo-matching tablets, orally, once daily after breakfast for up to 4 weeks in treatment period.
Drug: Placebo
TAK-438 placebo-matching tablets, orally, once daily after breakfast for 1 week in run-in period followed by TAK-438 10 mg tablets, orally, once daily after breakfast for up to 4 weeks in treatment period.
Drug: Placebo · Drug: TAK-438 10 mg
TAK-438 placebo-matching tablets
TAK-438 tablets
Percentage of Days Without Symptoms of Heartburn
Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. Reported data was the percentage of days for each group, calculated by the number of days without heartburn divided by the number of days of treatment period.
Time frame: Up to Week 4
Cumulative Rate of Improvement in Symptoms of Heartburn
Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. Cumulative rate of improvement was calculated as percentage of participants who experienced symptom improvement. Symptom improvement was defined as symptoms experienced on less than 2 days of the last 7 days. The cumulative data was collected between Day 0 and Day 24 and is reported for the following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24. Data not collected were shown as NA = Not Applicable.
Time frame: Day 0 to Day 24
Severity of Symptoms of Heartburn
Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. The severity of heartburn was calculated by the number of severity score in daily diaries.
Time frame: Up to Week 4
Percentage of Days Without Symptoms of Heartburn in Subgroup Stratified by Response (Improved or Not Improved) at Week 2
Participants recorded the presence and severity of heartburn in a daily participant diary. Percentage of days without heartburn was calculated in each subgroup of the response (improved or not improved) according to Criteria 1, i.e. Improved: the participants experienced heartburn on less than 2 days of the 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: the participants experienced heartburn on 2 days or more of the 7 days prior to Week 2 \[Day 8 through Day 14\] and Criteria 2, i.e. Improved: the proportion of days the participants experienced heartburn during the treatment period up to Week 2 \[Day 14\] was lower than that during the run-in period; Not improved: the proportion of days the participants experienced heartburn during the treatment period up to Week 2 \[Day 14\] was equal to or larger than that during the run-in period.
Time frame: Up to Week 4
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Improved Per Criteria 1) at Week 2
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. Cumulative rate of improvement was calculated as percentage of participants who experienced symptom improvement. The response was evaluated per Criteria 1, i.e. Improved: the participants experienced heartburn on less than 2 days of the 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: the participants experienced heartburn on 2 days or more of the 7 days prior to Week 2 \[Day 8 through Day 14\]. Cumulative data was collected between Day 0 and Day 22 and is reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 11, 15, 16, 17, 18, 19, 20, 21, and 22. Data not collected were shown as NA = Not Applicable.
Time frame: Day 0 to Day 22
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Not Improved Per Criteria 1) at Week 2
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. Cumulative rate of improvement is calculated as percentage of participants who experienced symptom improvement. The response was evaluated per Criteria 1, i.e. Improved: the participants experienced heartburn on less than 2 days of the 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: the participants experienced heartburn on 2 days or more of the 7 days prior to Week 2 \[Day 8 through Day 14\]. Cumulative data was collected between Day 0 and Day 24 and is reported for following time points: Days 0, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24. Data not collected were shown as NA = Not Applicable.
Time frame: Day 0 to Day 24
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Improved Per Criteria 2) at Week 2
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in daily participant diary. The score range was 0-4, with higher scores reflecting the greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response evaluated per Criteria 2, i.e. Improved: proportion of days participant experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than that during run-in period; Not improved: proportion of days participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal to or larger than that during the run-in period. Cumulative data was collected between Day 0 and Day 24 and is reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24. Data not collected were shown as NA=Not Applicable.
Time frame: Day 0 to Day 24
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Not Improved Per Criteria 2) at Week 2
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in daily participant diary. The score range was 0-4, with higher scores reflecting the greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. The response evaluated per Criteria 2, i.e. Improved: proportion of days participant experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than that during run-in period; Not improved: proportion of days participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal to or larger than that during run-in period. Cumulative data was collected between Day 0 and Day 24 and is reported for following time points: Days 0, 5, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24. Data not collected shown as NA=Not Applicable.
Time frame: Day 0 to Day 24
Severity of Symptoms of Heartburn in Subgroup Stratified by Response (Improved or Not Improved) at Week 2
Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, the higher scores indicates greater severity. The severity was calculated in each subgroup of response (improved or not improved) according to Criteria 1, i.e. Improved: participants experienced heartburn on less than 2 days of the 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: participants experienced heartburn on 2 days or more of the 7 days prior to Week 2 \[Day 8 through Day 14\] and Criteria 2, i.e. Improved: proportion of days the participants experienced heartburn during the treatment period up to Week 2 \[Day 14\] was lower than that during the run-in period; Not improved: proportion of days the participants experienced heartburn during the treatment period up to Week 2 \[Day 14\] was equal to or larger than that during the run-in period.
Time frame: Up to Week 4
Percentage of Days Without Symptoms of Heartburn in Subgroup Stratified by Endoscopic Findings (the Modified LA Classification Grade N or M) at Baseline
Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, higher scores indicates greater severity. The percentage was calculated in each subgroup of the endoscopic findings where Grade N: normal mucosa; Grade M: minimal changes to the mucosa, such as erythema and/or whitish turbidity; Grade A: non-confluent mucosal breaks \<5mm in length; Grade B: non-confluent mucosal breaks ≥5mm in length; Grade C: confluent mucosal breaks \<75% circumferential; Grade D: confluent mucosal breaks \>75% circumferential.
Time frame: Up to Week 4
Cumulative Rate of Improvement in Heartburn in Subgroup Stratified by Endoscopic Findings (the Modified LA Classification Grade N) at Baseline
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. The score range was 0-4, higher scores indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Cumulative rate calculated in subgroup of Grade N per modified LA classification. Modified LA classification Grade N: normal mucosa; Grade M: minimal changes to mucosa; Grade A: nonconfluent mucosal breaks \<5mm in length; Grade B: non-confluent mucosal breaks ≥5mm in length; Grade C: confluent mucosal breaks \<75% circumferential; Grade D: confluent mucosal breaks \>75% circumferential. Cumulative data collected between Day 0 and 24 and reported for time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24. Data not collected shown as NA=Not Applicable.
Time frame: Day 0 to Day 24
Cumulative Rate of Improvement in Heartburn in Subgroup Stratified by Endoscopic Findings (the Modified LA Classification Grade M) at Baseline
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher scores indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Cumulative rate calculated in subgroup of Grade M per modified LA classification. Modified LA classification Grade N: normal mucosa; Grade M: minimal changes to mucosa; Grade A: nonconfluent mucosal breaks \<5mm in length; Grade B: non-confluent mucosal breaks ≥5mm in length; Grade C: confluent mucosal breaks \<75% circumferential; Grade D: confluent mucosal breaks \>75% circumferential. Cumulative data collected between Day 0 and 24 and reported for time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24. Data not collected shown as NA=Not Applicable.
Time frame: Day 0 to Day 24
Severity of Symptoms of Heartburn in Subgroup Stratified by Endoscopic Findings (the Modified LA Classification Grade N or M) at Baseline
Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. The severity of heartburn was calculated in each subgroup of the endoscopic findings where Grade N: normal mucosa; Grade M: minimal changes to the mucosa, such as erythema and/or whitish turbidity; Grade A: non-confluent mucosal breaks \<5mm in length; Grade B: non-confluent mucosal breaks ≥5mm in length; Grade C: confluent mucosal breaks \<75% circumferential; Grade D: confluent mucosal breaks \>75% circumferential.
Time frame: Up to Week 4
Percentage of Days Without Symptoms of Heartburn Stratified by Subgroup of Both the Response at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N or M)
Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, higher scores indicates greater severity. The percentage was calculated in each subgroup (response; Grade N and improved, response; Grade N and not improved, response; Grade M and improved, response; Grade M and not improved) according to Criteria 1 and 2. The modified LA classification Grade N indicates the participants with normal mucosa and Grade M indicates the participants with minimal changes to the mucosa.
Time frame: Up to Week 4
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Improved Per Criteria 1) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N)
Participants recorded the presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher scores indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 1, i.e. Improved: participants experienced heartburn on less than 2 days of 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: participants experienced heartburn on 2 days or more of the 7 days prior to Week 2 \[Day 8 through Day 14\]. Modified LA classification Grade N: normal mucosa and Grade M: minimal changes to the mucosa. Cumulative data was collected between Day 0 and Day 22 and is reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 11, 19, 20, and 22. Data not collected were shown as NA=Not Applicable.
Time frame: Day 0 to Day 22
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Not Improved Per Criteria 1) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N)
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher scores indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 1, i.e. Improved: participants experienced heartburn on less than 2 days of 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: participants experienced heartburn on 2 days or more of 7 days prior to Week 2 \[Day 8 through Day 14\]. Modified LA classification Grade N indicates participants with normal mucosa and Grade M indicates participants with minimal changes to mucosa). Cumulative data was collected between Day 0 and Day 22 and is reported for following time points: Days 0, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 and 22. Data not collected were shown as NA=Not Applicable.
Time frame: Day 0 to Day 24
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Improved Per Criteria 1) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade M)
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 1, i.e. Improved: participants experienced heartburn on less than 2 days of 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: participants experienced heartburn on 2 days or more of 7 days prior to Week 2 \[Day 8 through Day 14\]. Modified LA classification Grade N indicates participants with normal mucosa and Grade M indicates participants with minimal changes to mucosa). Cumulative data collected between Day 0 and Day 22 and is reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 11, 15, 16, 17, 18, 20, 21 and 22. Data not collected were shown as NA=Not Applicable.
Time frame: Day 0 to Day 22
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Not Improved Per Criteria 1) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade M)
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in a daily participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response evaluated per Criteria 1, i.e. Improved: participants experienced heartburn on \< 2 days of the 7 days prior to Week 2 \[Day 8 to 14\]; Not improved: participants experienced heartburn on \>= 2 days of 7 days prior to Week 2 \[Day 8 to 14\]. Modified LA classification Grade N indicates participants with normal mucosa and Grade M indicates participants with minimal changes to mucosa). Cumulative data collected between Day 0 and 24 and reported for following time points: Days 0, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24. Data not collected were shown as NA=Not Applicable.
Time frame: Day 0 to Day 24
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Improved Per Criteria 2) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N)
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 2, i.e. Improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than during run-in period; Not improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal to or larger than during run-in period. Modified LA classification Grade N: normal mucosa and Grade M: minimal changes to mucosa). Cumulative data collected between Day 0 and 22 and reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, and 22. Data not collected shown as NA=Not Applicable.
Time frame: Day 0 to Day 22
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Not Improved Per Criteria 2) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N)
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement was calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 2, i.e. Improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than during run-in period; Not improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal to or larger than during run-in period. Modified LA classification Grade N: normal mucosa and Grade M: minimal changes to mucosa. Cumulative data was collected between Day 0 and Day 24 and is reported for following time points: Days 0, 5, 9, 11, 12, 13, 14, 19, 20, 21, 22, 23, and 24. Data not collected were shown as NA=Not Applicable.
Time frame: Day 0 to Day 24
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Improved Per Criteria 2) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade M)
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 2, i.e. Improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than during run-in period; Not improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal or larger than during run-in period. Modified LA classification Grade N: normal mucosa and Grade M: minimal changes to mucosa. Cumulative data collected between Day 0 and 24 and reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24. Data not collected shown as NA=Not Applicable.
Time frame: Day 0 to Day 24
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Both the Response (Not Improved Per Criteria 2) at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade M)
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe: 4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 2, i.e. Improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than during run-in period; Not improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal to or larger than during run-in period. Modified LA classification Grade N: normal mucosa and Grade M: minimal changes to mucosa). Cumulative data was collected between Day 0 and Day 23 and is reported for following time points: Days 0, 9, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23. Data not collected shown as NA=Not Applicable.
Time frame: Day 0 to Day 23
Severity of Symptoms of Heartburn in Subgroup Stratified by Both the Response at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N or M)
Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. The mean severity of heartburn was calculated in each subgroup (response; Grade N and improved, response; Grade N and not improved, response; Grade M and improved, response; Grade M and not improved) according to criteria 1 and 2. The modified LA classification Grade N indicates the participants with normal mucosa and Grade M indicates the participants with minimal changes to the mucosa.
Time frame: Up to Week 4
Percentage of Days Without Symptoms of Heartburn in Subgroup Stratified by Response (Improved or Not Improved) to Acid Suppressants in Participants Who Had a Medication History
Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, higher score indicates greater severity. The percentage was calculated in each subgroup of the response (improved or not improved) in the participants who had a medication history of any of acid suppressants. The acid suppressants include proton pump inhibitors \[PPIs\], histamine H2-receptor antagonists \[H2RAs\], or other agents \[anticholinergics or anti-gastrin drugs\].
Time frame: Up to Week 4
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Improved) to Acid Suppressants in Participants Who Had a Medication History
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Cumulative improvement rate calculated in each subgroup of the response (improved or not improved) in participants who had medication history of any of acid suppressants. Acid suppressants include proton pump inhibitors \[PPIs\], histamine H2-receptor antagonists \[H2RAs\], or other agents \[anticholinergics or anti-gastrin drugs\]. Cumulative data collected between Day 0 and Day 23 and is reported for following time points: Days 0, 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 and 23. Data not collected were shown as NA=Not Applicable.
Time frame: Up to Week 4
Cumulative Rate of Improvement in Symptoms of Heartburn in Subgroup Stratified by Response (Not Improved) to Acid Suppressants in Participants Who Had a Medication History
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Cumulative improvement rate calculated in each subgroup of the response (improved or not improved) in participants who had medication history of any of acid suppressants. Acid suppressants include proton pump inhibitors \[PPIs\], histamine H2-receptor antagonists \[H2RAs\], or other agents \[anticholinergics or anti-gastrin drugs\]. Cumulative data was collected between Day 0 and Day 23 and is reported for following time points: Days 0, 1, 5, 9, 16, 19, and 20. Data not collected were shown as NA=Not Applicable.
Time frame: Up to Week 4
Severity of Symptoms of Heartburn in Subgroup Stratified by Response (Improved or Not Improved) to Acid Suppressants in Participants Who Had a Medication History
Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. The mean severity of heartburn was calculated in each subgroup of the response (improved or not improved) in the participants who had a medication history of any of acid suppressants. The acid suppressants include proton pump inhibitors \[PPIs\], histamine H2-receptor antagonists \[H2RAs\], or other agents \[anticholinergics or anti-gastrin drugs\].
Time frame: Up to Week 4
Participants took part in the study at 44 investigative sites in Japan from 15 November 2016 to 26 February 2018.
| Milestone | Placebo | TAK-438 10 mg |
|---|---|---|
| Started | 245 | 239 |
| Treated | 245 | 238 |
| Completed | 243 | 234 |
| Not completed | 2 | 5 |
| Withdrew: Randomized but not treated | 0 | 1 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Withdrawal by participant | 0 | 1 |
Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. Reported data was the percentage of days for each group, calculated by the number of days without heartburn divided by the number of days of treatment period.
| percentage of days | Placebo | TAK-438 10 mg |
|---|---|---|
| Percentage of Days Without Symptoms of Heartburn | 61.50 (0.0 to 100.0) | 72.55 (0.0 to 100.0) |
Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. Cumulative rate of improvement was calculated as percentage of participants who experienced symptom improvement. Symptom improvement was defined as symptoms experienced on less than 2 days of the last 7 days. The cumulative data was collected between Day 0 and Day 24 and is reported for the following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24. Data not collected were shown as NA = Not Applicable.
| percentage of participants | Placebo | TAK-438 10 mg |
|---|---|---|
| Day 0 | 0.0 | 0.0 |
| Day 1 | 14.7 | 23.1 |
| Day 2 | 15.9 | 24.4 |
| Day 3 | 16.3 | 25.2 |
| Day 4 | 17.6 | 26.1 |
| Day 5 | 18.8 | 28.2 |
| Day 6 | 19.2 | 30.4 |
| Day 7 | 20.0 | 32.5 |
| Day 8 | 21.2 | 32.9 |
| Day 9 | 23.7 | 34.2 |
| Day 10 | NA | 35.5 |
| Day 11 | 25.7 | 38.5 |
| Day 12 | 27.3 | 41.1 |
| Day 13 | 29.0 | 44.6 |
| Day 14 | 30.6 | 46.7 |
| Day 15 | 31.4 | 48.9 |
| Day 16 | 34.3 | 49.7 |
| Day 17 | 36.3 | 51.0 |
| Day 18 | 38.4 | 54.4 |
| Day 19 | 40.0 | 55.7 |
| Day 20 | 42.7 | 59.0 |
| Day 21 | 44.7 | 59.5 |
| Day 22 | 48.6 | 62.7 |
| Day 23 | 51.3 | 66.1 |
| Day 24 | NA | 71.3 |
Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. The severity of heartburn was calculated by the number of severity score in daily diaries.
| score on a scale | Placebo | TAK-438 10 mg |
|---|---|---|
| Severity of Symptoms of Heartburn | 1.140 (0.00 to 2.82) | 1.070 (0.00 to 3.67) |
Participants recorded the presence and severity of heartburn in a daily participant diary. Percentage of days without heartburn was calculated in each subgroup of the response (improved or not improved) according to Criteria 1, i.e. Improved: the participants experienced heartburn on less than 2 days of the 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: the participants experienced heartburn on 2 days or more of the 7 days prior to Week 2 \[Day 8 through Day 14\] and Criteria 2, i.e. Improved: the proportion of days the participants experienced heartburn during the treatment period up to Week 2 \[Day 14\] was lower than that during the run-in period; Not improved: the proportion of days the participants experienced heartburn during the treatment period up to Week 2 \[Day 14\] was equal to or larger than that during the run-in period.
| percentage of days | Placebo | TAK-438 10 mg |
|---|---|---|
| Criteria 1, Improved | 92.00 (41.4 to 100.0) | 96.00 (46.4 to 100.0) |
| Criteria 1, Not Improved | 50.95 (0.0 to 92.9) | 48.05 (0.0 to 92.9) |
| Criteria 2, Improved | 71.40 (3.3 to 100.0) | 81.15 (14.3 to 100.0) |
| Criteria 2, Not Improved | 39.30 (0.0 to 83.3) | 24.15 (0.0 to 84.0) |
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. Cumulative rate of improvement was calculated as percentage of participants who experienced symptom improvement. The response was evaluated per Criteria 1, i.e. Improved: the participants experienced heartburn on less than 2 days of the 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: the participants experienced heartburn on 2 days or more of the 7 days prior to Week 2 \[Day 8 through Day 14\]. Cumulative data was collected between Day 0 and Day 22 and is reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 11, 15, 16, 17, 18, 19, 20, 21, and 22. Data not collected were shown as NA = Not Applicable.
| percentage of participants | Placebo | TAK-438 10 mg |
|---|---|---|
| Day 0 | 0.0 | 0.0 |
| Day 1 | 43.4 | 55.6 |
| Day 2 | 47.0 | 58.6 |
| Day 3 | 48.2 | 60.6 |
| Day 4 | 51.8 | 62.6 |
| Day 5 | 55.4 | 67.7 |
| Day 6 | 56.6 | 72.7 |
| Day 7 | 59.0 | 77.8 |
| Day 8 | 62.7 | 78.8 |
| Day 11 | NA | 80.8 |
| Day 15 | NA | 81.8 |
| Day 16 | 63.9 | NA |
| Day 17 | 65.1 | NA |
| Day 18 | NA | 83.8 |
| Day 19 | 66.3 | NA |
| Day 20 | 69.2 | 87.6 |
| Day 21 | 70.6 | NA |
| Day 22 | 75.5 | 93.8 |
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. Cumulative rate of improvement is calculated as percentage of participants who experienced symptom improvement. The response was evaluated per Criteria 1, i.e. Improved: the participants experienced heartburn on less than 2 days of the 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: the participants experienced heartburn on 2 days or more of the 7 days prior to Week 2 \[Day 8 through Day 14\]. Cumulative data was collected between Day 0 and Day 24 and is reported for following time points: Days 0, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24. Data not collected were shown as NA = Not Applicable.
| percentage of participants | Placebo | TAK-438 10 mg |
|---|---|---|
| Day 0 | 0.0 | 0.0 |
| Day 9 | 3.7 | 2.2 |
| Day 10 | NA | 4.4 |
| Day 11 | 6.8 | 8.1 |
| Day 12 | 9.3 | 12.6 |
| Day 13 | 11.7 | 18.5 |
| Day 14 | 14.2 | 22.2 |
| Day 15 | 15.4 | 25.2 |
| Day 16 | 19.1 | 26.7 |
| Day 17 | 21.6 | 28.9 |
| Day 18 | 24.7 | 33.3 |
| Day 19 | 26.6 | 35.6 |
| Day 20 | 29.2 | 38.7 |
| Day 21 | 31.5 | 39.5 |
| Day 22 | 34.9 | 41.7 |
| Day 23 | 39.2 | 47.0 |
| Day 24 | NA | 55.1 |
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in daily participant diary. The score range was 0-4, with higher scores reflecting the greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response evaluated per Criteria 2, i.e. Improved: proportion of days participant experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than that during run-in period; Not improved: proportion of days participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal to or larger than that during the run-in period. Cumulative data was collected between Day 0 and Day 24 and is reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24. Data not collected were shown as NA=Not Applicable.
| percentage of participants | Placebo | TAK-438 10 mg |
|---|---|---|
| Day 0 | 0.0 | 0.0 |
| Day 1 | 21.4 | 31.6 |
| Day 2 | 23.2 | 33.3 |
| Day 3 | 23.8 | 34.5 |
| Day 4 | 25.6 | 35.6 |
| Day 5 | 26.2 | 38.5 |
| Day 6 | 26.8 | 41.4 |
| Day 7 | 28.0 | 44.3 |
| Day 8 | 29.8 | 44.9 |
| Day 9 | 32.1 | 46.0 |
| Day 10 | NA | 47.8 |
| Day 11 | 34.5 | 51.8 |
| Day 12 | 36.9 | 54.1 |
| Day 13 | 38.7 | 57.6 |
| Day 14 | NA | 58.2 |
| Day 15 | 39.3 | 60.0 |
| Day 16 | 42.3 | 61.1 |
| Day 17 | 45.3 | 62.3 |
| Day 18 | 47.1 | 65.2 |
| Day 19 | 48.3 | 66.3 |
| Day 20 | 50.9 | 69.5 |
| Day 21 | 52.4 | 70.1 |
| Day 22 | 56.7 | 71.9 |
| Day 23 | NA | 74.5 |
| Day 24 | NA | 78.7 |
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in daily participant diary. The score range was 0-4, with higher scores reflecting the greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. The response evaluated per Criteria 2, i.e. Improved: proportion of days participant experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than that during run-in period; Not improved: proportion of days participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal to or larger than that during run-in period. Cumulative data was collected between Day 0 and Day 24 and is reported for following time points: Days 0, 5, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24. Data not collected shown as NA=Not Applicable.
| percentage of participants | Placebo | TAK-438 10 mg |
|---|---|---|
| Day 0 | 0.0 | 0.0 |
| Day 5 | 2.6 | NA |
| Day 9 | 5.2 | 1.6 |
| Day 11 | 6.5 | NA |
| Day 12 | NA | 4.9 |
| Day 13 | 7.8 | 8.2 |
| Day 14 | 13.0 | 14.8 |
| Day 15 | 14.3 | 18.0 |
| Day 16 | 16.9 | NA |
| Day 17 | NA | 19.7 |
| Day 18 | 19.5 | 24.6 |
| Day 19 | 22.1 | 26.2 |
| Day 20 | 24.9 | 29.7 |
| Day 21 | 27.9 | NA |
| Day 22 | 31.3 | 37.0 |
| Day 23 | 41.1 | 42.7 |
| Day 24 | NA | 50.9 |
Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, the higher scores indicates greater severity. The severity was calculated in each subgroup of response (improved or not improved) according to Criteria 1, i.e. Improved: participants experienced heartburn on less than 2 days of the 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: participants experienced heartburn on 2 days or more of the 7 days prior to Week 2 \[Day 8 through Day 14\] and Criteria 2, i.e. Improved: proportion of days the participants experienced heartburn during the treatment period up to Week 2 \[Day 14\] was lower than that during the run-in period; Not improved: proportion of days the participants experienced heartburn during the treatment period up to Week 2 \[Day 14\] was equal to or larger than that during the run-in period.
| score on a scale | Placebo | TAK-438 10 mg |
|---|---|---|
| Criteria 1, Improved | 0.420 (0.00 to 1.44) | 0.310 (0.00 to 1.56) |
| Criteria 1, Not Improved | 1.430 (0.25 to 2.82) | 1.420 (0.14 to 2.64) |
| Criteria 2, Improved | 0.960 (0.00 to 2.14) | 0.675 (0.00 to 2.04) |
| Criteria 2, Not Improved | 1.610 (0.44 to 2.82) | 1.740 (0.43 to 3.67) |
Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, higher scores indicates greater severity. The percentage was calculated in each subgroup of the endoscopic findings where Grade N: normal mucosa; Grade M: minimal changes to the mucosa, such as erythema and/or whitish turbidity; Grade A: non-confluent mucosal breaks \<5mm in length; Grade B: non-confluent mucosal breaks ≥5mm in length; Grade C: confluent mucosal breaks \<75% circumferential; Grade D: confluent mucosal breaks \>75% circumferential.
| percentage of days | Placebo | TAK-438 10 mg |
|---|---|---|
| Grade N | 64.15 (0.0 to 100.0) | 76.70 (0.0 to 100.0) |
| Grade M | 60.70 (0.0 to 100.0) | 67.90 (0.0 to 100.0) |
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. The score range was 0-4, higher scores indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Cumulative rate calculated in subgroup of Grade N per modified LA classification. Modified LA classification Grade N: normal mucosa; Grade M: minimal changes to mucosa; Grade A: nonconfluent mucosal breaks \<5mm in length; Grade B: non-confluent mucosal breaks ≥5mm in length; Grade C: confluent mucosal breaks \<75% circumferential; Grade D: confluent mucosal breaks \>75% circumferential. Cumulative data collected between Day 0 and 24 and reported for time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24. Data not collected shown as NA=Not Applicable.
| percentage of participants | Placebo | TAK-438 10 mg |
|---|---|---|
| Day 0 | 0.0 | 0.0 |
| Day 1 | 18.3 | 22.2 |
| Day 2 | NA | 23.5 |
| Day 3 | 19.5 | 24.7 |
| Day 4 | NA | 27.2 |
| Day 5 | 23.2 | 29.7 |
| Day 6 | 24.4 | 32.3 |
| Day 7 | 26.8 | 36.0 |
| Day 8 | 28.0 | 37.3 |
| Day 9 | 29.3 | 41.0 |
| Day 11 | 34.1 | 43.5 |
| Day 12 | 36.6 | 47.3 |
| Day 13 | NA | 51.1 |
| Day 14 | NA | 54.8 |
| Day 15 | NA | 57.3 |
| Day 16 | 39.0 | NA |
| Day 17 | 40.2 | 58.6 |
| Day 18 | 43.9 | 61.1 |
| Day 19 | 46.3 | 63.6 |
| Day 20 | 47.7 | 66.3 |
| Day 21 | 49.1 | 67.7 |
| Day 22 | 52.1 | 73.4 |
| Day 23 | NA | 78.7 |
| Day 24 | NA | 89.4 |
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher scores indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Cumulative rate calculated in subgroup of Grade M per modified LA classification. Modified LA classification Grade N: normal mucosa; Grade M: minimal changes to mucosa; Grade A: nonconfluent mucosal breaks \<5mm in length; Grade B: non-confluent mucosal breaks ≥5mm in length; Grade C: confluent mucosal breaks \<75% circumferential; Grade D: confluent mucosal breaks \>75% circumferential. Cumulative data collected between Day 0 and 24 and reported for time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24. Data not collected shown as NA=Not Applicable.
| percentage of participants | Placebo | TAK-438 10 mg |
|---|---|---|
| Day 0 | 0.0 | 0.0 |
| Day 1 | 12.9 | 23.6 |
| Day 2 | 14.7 | 24.9 |
| Day 3 | NA | 25.5 |
| Day 4 | 16.6 | NA |
| Day 5 | NA | 27.5 |
| Day 6 | NA | 29.4 |
| Day 7 | NA | 30.7 |
| Day 8 | 17.8 | NA |
| Day 9 | 20.9 | NA |
| Day 10 | NA | 32.7 |
| Day 11 | 21.5 | 35.9 |
| Day 12 | 22.7 | 37.9 |
| Day 13 | 25.2 | 41.2 |
| Day 14 | 27.6 | 42.5 |
| Day 15 | 28.8 | 44.4 |
| Day 16 | 31.9 | 45.7 |
| Day 17 | 34.4 | 47.0 |
| Day 18 | 35.6 | 51.0 |
| Day 19 | 36.9 | 51.6 |
| Day 20 | 40.3 | 55.1 |
| Day 21 | 42.6 | NA |
| Day 22 | 47.0 | 57.1 |
| Day 23 | 50.8 | 59.6 |
| Day 24 | NA | 63.3 |
Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. The severity of heartburn was calculated in each subgroup of the endoscopic findings where Grade N: normal mucosa; Grade M: minimal changes to the mucosa, such as erythema and/or whitish turbidity; Grade A: non-confluent mucosal breaks \<5mm in length; Grade B: non-confluent mucosal breaks ≥5mm in length; Grade C: confluent mucosal breaks \<75% circumferential; Grade D: confluent mucosal breaks \>75% circumferential.
| score on a scale | Placebo | TAK-438 10 mg |
|---|---|---|
| Grade N | 1.070 (0.00 to 2.82) | 0.850 (0.00 to 3.67) |
| Grade M | 1.180 (0.00 to 2.54) | 1.110 (0.00 to 2.64) |
Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, higher scores indicates greater severity. The percentage was calculated in each subgroup (response; Grade N and improved, response; Grade N and not improved, response; Grade M and improved, response; Grade M and not improved) according to Criteria 1 and 2. The modified LA classification Grade N indicates the participants with normal mucosa and Grade M indicates the participants with minimal changes to the mucosa.
| percentage of days | Placebo | TAK-438 10 mg |
|---|---|---|
| Criteria 1, Grade N and Improved | 93.00 (41.4 to 100.0) | 92.90 (46.4 to 100.0) |
| Criteria 1, Grade N and Not Improved | 53.60 (0.0 to 92.6) | 53.60 (0.0 to 92.9) |
| Criteria 1, Grade M and Improved | 89.30 (56.0 to 100.0) | 96.40 (59.3 to 100.0) |
| Criteria 1, Grade M and Not Improved | 49.05 (0.0 to 92.9) | 44.40 (0.0 to 92.9) |
| Criteria 2, Grade N and Improved | 69.00 (3.6 to 100.0) | 79.30 (39.3 to 100.0) |
| Criteria 2, Grade N and Not Improved | 50.00 (0.0 to 83.3) | 22.95 (0.0 to 84.0) |
| Criteria 2, Grade M and Improved | 73.30 (3.3 to 100.0) | 82.10 (14.3 to 100.0) |
| Criteria 2, Grade M and Not Improved | 33.90 (0.0 to 78.6) | 25.00 (0.0 to 78.6) |
Participants recorded the presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher scores indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 1, i.e. Improved: participants experienced heartburn on less than 2 days of 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: participants experienced heartburn on 2 days or more of the 7 days prior to Week 2 \[Day 8 through Day 14\]. Modified LA classification Grade N: normal mucosa and Grade M: minimal changes to the mucosa. Cumulative data was collected between Day 0 and Day 22 and is reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 11, 19, 20, and 22. Data not collected were shown as NA=Not Applicable.
| percentage of participants | Placebo | TAK-438 10 mg |
|---|---|---|
| Day 0 | 0.0 | 0.0 |
| Day 1 | 53.6 | 46.2 |
| Day 2 | NA | 48.7 |
| Day 3 | 57.1 | 51.3 |
| Day 4 | NA | 56.4 |
| Day 5 | 67.9 | 61.5 |
| Day 6 | 71.4 | 66.7 |
| Day 7 | 78.6 | 74.4 |
| Day 8 | 82.1 | 76.9 |
| Day 11 | NA | 79.5 |
| Day 19 | 85.7 | NA |
| Day 20 | NA | 82.9 |
| Day 22 | 89.3 | 100.0 |
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher scores indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 1, i.e. Improved: participants experienced heartburn on less than 2 days of 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: participants experienced heartburn on 2 days or more of 7 days prior to Week 2 \[Day 8 through Day 14\]. Modified LA classification Grade N indicates participants with normal mucosa and Grade M indicates participants with minimal changes to mucosa). Cumulative data was collected between Day 0 and Day 22 and is reported for following time points: Days 0, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 and 22. Data not collected were shown as NA=Not Applicable.
| percentage of participants | Placebo | TAK-438 10 mg |
|---|---|---|
| Day 0 | 0.0 | 0.0 |
| Day 9 | 1.9 | 7.3 |
| Day 11 | 9.3 | 9.8 |
| Day 12 | 13.0 | 17.1 |
| Day 13 | NA | 24.4 |
| Day 14 | NA | 31.7 |
| Day 15 | NA | 36.6 |
| Day 16 | 16.7 | NA |
| Day 17 | 18.5 | 39.0 |
| Day 18 | 24.1 | 43.9 |
| Day 19 | 25.9 | 48.8 |
| Day 20 | 27.9 | 51.2 |
| Day 21 | 30.1 | 53.8 |
| Day 22 | 32.4 | NA |
| Day 23 | NA | 63.0 |
| Day 24 | NA | 81.5 |
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 1, i.e. Improved: participants experienced heartburn on less than 2 days of 7 days prior to Week 2 \[Day 8 through Day 14\]; Not improved: participants experienced heartburn on 2 days or more of 7 days prior to Week 2 \[Day 8 through Day 14\]. Modified LA classification Grade N indicates participants with normal mucosa and Grade M indicates participants with minimal changes to mucosa). Cumulative data collected between Day 0 and Day 22 and is reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 11, 15, 16, 17, 18, 20, 21 and 22. Data not collected were shown as NA=Not Applicable.
| percentage of participants | Placebo | TAK-438 10 mg |
|---|---|---|
| Day 0 | 0.0 | 0.0 |
| Day 1 | 38.2 | 61.7 |
| Day 2 | 43.6 | 65.0 |
| Day 3 | NA | 66.7 |
| Day 4 | 49.1 | NA |
| Day 5 | NA | 71.7 |
| Day 6 | NA | 76.7 |
| Day 7 | NA | 80.0 |
| Day 8 | 52.7 | NA |
| Day 11 | NA | 81.7 |
| Day 15 | NA | 83.3 |
| Day 16 | 54.5 | NA |
| Day 17 | 56.4 | NA |
| Day 18 | NA | 86.7 |
| Day 20 | 60.8 | 90.5 |
| Day 21 | 63.0 | NA |
| Day 22 | 68.3 | NA |
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in a daily participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response evaluated per Criteria 1, i.e. Improved: participants experienced heartburn on \< 2 days of the 7 days prior to Week 2 \[Day 8 to 14\]; Not improved: participants experienced heartburn on \>= 2 days of 7 days prior to Week 2 \[Day 8 to 14\]. Modified LA classification Grade N indicates participants with normal mucosa and Grade M indicates participants with minimal changes to mucosa). Cumulative data collected between Day 0 and 24 and reported for following time points: Days 0, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24. Data not collected were shown as NA=Not Applicable.
| percentage of participants | Placebo | TAK-438 10 mg |
|---|---|---|
| Day 0 | 0.0 | 0.0 |
| Day 9 | 4.6 | NA |
| Day 10 | NA | 3.2 |
| Day 11 | 5.6 | 7.4 |
| Day 12 | 7.4 | 10.6 |
| Day 13 | 11.1 | 16.0 |
| Day 14 | 14.8 | 18.1 |
| Day 15 | 16.7 | 20.2 |
| Day 16 | 20.4 | 22.3 |
| Day 17 | 23.1 | 24.5 |
| Day 18 | 25.0 | 28.7 |
| Day 19 | 26.9 | 29.8 |
| Day 20 | 29.9 | 33.2 |
| Day 21 | 32.2 | NA |
| Day 22 | 36.2 | 36.4 |
| Day 23 | 42.0 | 40.1 |
| Day 24 | NA | 45.6 |
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 2, i.e. Improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than during run-in period; Not improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal to or larger than during run-in period. Modified LA classification Grade N: normal mucosa and Grade M: minimal changes to mucosa). Cumulative data collected between Day 0 and 22 and reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, and 22. Data not collected shown as NA=Not Applicable.
| percentage of participants | Placebo | TAK-438 10 mg |
|---|---|---|
| Day 0 | 0.0 | 0.0 |
| Day 1 | 25.4 | 29.5 |
| Day 2 | NA | 31.1 |
| Day 3 | 27.1 | 32.8 |
| Day 4 | NA | 36.1 |
| Day 5 | 28.8 | 39.3 |
| Day 6 | 30.5 | 42.6 |
| Day 7 | 33.9 | 47.5 |
| Day 8 | 35.6 | 49.2 |
| Day 9 | NA | 52.5 |
| Day 11 | 40.7 | 55.7 |
| Day 12 | 44.1 | 59.0 |
| Day 13 | NA | 62.3 |
| Day 14 | NA | 63.9 |
| Day 15 | NA | 67.2 |
| Day 16 | 47.5 | NA |
| Day 17 | 49.2 | 68.9 |
| Day 18 | 54.2 | 72.1 |
| Day 19 | 55.9 | 73.8 |
| Day 20 | NA | 77.5 |
| Day 21 | NA | 79.4 |
| Day 22 | 58.1 | 84.5 |
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement was calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 2, i.e. Improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than during run-in period; Not improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal to or larger than during run-in period. Modified LA classification Grade N: normal mucosa and Grade M: minimal changes to mucosa. Cumulative data was collected between Day 0 and Day 24 and is reported for following time points: Days 0, 5, 9, 11, 12, 13, 14, 19, 20, 21, 22, 23, and 24. Data not collected were shown as NA=Not Applicable.
| percentage of participants | Placebo | TAK-438 10 mg |
|---|---|---|
| Day 0 | 0.0 | 0.0 |
| Day 5 | 8.7 | NA |
| Day 9 | 13.0 | 5.3 |
| Day 11 | 17.4 | NA |
| Day 12 | NA | 10.5 |
| Day 13 | NA | 15.8 |
| Day 14 | NA | 26.3 |
| Day 19 | 21.7 | 31.6 |
| Day 20 | 26.3 | NA |
| Day 21 | 30.9 | NA |
| Day 22 | 35.9 | 39.2 |
| Day 23 | NA | 59.5 |
| Day 24 | NA | 100.0 |
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 2, i.e. Improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than during run-in period; Not improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal or larger than during run-in period. Modified LA classification Grade N: normal mucosa and Grade M: minimal changes to mucosa. Cumulative data collected between Day 0 and 24 and reported for following time points: Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24. Data not collected shown as NA=Not Applicable.
| percentage of participants | Placebo | TAK-438 10 mg |
|---|---|---|
| Day 0 | 0.0 | 0.0 |
| Day 1 | 19.3 | 32.7 |
| Day 2 | 22.0 | 34.5 |
| Day 3 | NA | 35.4 |
| Day 4 | 24.8 | NA |
| Day 5 | NA | 38.1 |
| Day 6 | NA | 40.7 |
| Day 7 | NA | 42.5 |
| Day 8 | 26.6 | NA |
| Day 9 | 30.3 | NA |
| Day 10 | NA | 45.2 |
| Day 11 | 31.2 | 49.7 |
| Day 12 | 33.0 | 51.5 |
| Day 13 | 35.8 | 55.1 |
| Day 15 | 36.7 | 56.0 |
| Day 16 | 39.4 | 57.8 |
| Day 17 | 43.2 | 58.7 |
| Day 18 | NA | 61.4 |
| Day 19 | 44.1 | 62.3 |
| Day 20 | 48.2 | 65.1 |
| Day 21 | 50.6 | NA |
| Day 22 | 56.1 | NA |
| Day 23 | NA | 69.0 |
| Day 24 | NA | 75.2 |
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe: 4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Response was evaluated per Criteria 2, i.e. Improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was lower than during run-in period; Not improved: participants experienced heartburn during treatment period up to Week 2 \[Day 14\] was equal to or larger than during run-in period. Modified LA classification Grade N: normal mucosa and Grade M: minimal changes to mucosa). Cumulative data was collected between Day 0 and Day 23 and is reported for following time points: Days 0, 9, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23. Data not collected shown as NA=Not Applicable.
| percentage of participants | Placebo | TAK-438 10 mg |
|---|---|---|
| Day 0 | 0.0 | 0.0 |
| Day 9 | 1.9 | NA |
| Day 12 | NA | 2.4 |
| Day 13 | 3.7 | 4.8 |
| Day 14 | 11.1 | 9.5 |
| Day 15 | 13.0 | 14.3 |
| Day 16 | 16.7 | NA |
| Day 17 | NA | 16.7 |
| Day 18 | 20.4 | 23.8 |
| Day 19 | 22.3 | NA |
| Day 20 | 24.3 | 29.1 |
| Day 21 | 26.5 | NA |
| Day 22 | 29.0 | 36.2 |
| Day 23 | 43.2 | NA |
Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. The mean severity of heartburn was calculated in each subgroup (response; Grade N and improved, response; Grade N and not improved, response; Grade M and improved, response; Grade M and not improved) according to criteria 1 and 2. The modified LA classification Grade N indicates the participants with normal mucosa and Grade M indicates the participants with minimal changes to the mucosa.
| score on a scale | Placebo | TAK-438 10 mg |
|---|---|---|
| Criteria 1, Grade N and Improved | 0.510 (0.00 to 1.31) | 0.430 (0.00 to 1.56) |
| Criteria 1, Grade N and Not Improved | 1.375 (0.59 to 2.82) | 1.240 (0.14 to 2.48) |
| Criteria 1, Grade M and Improved | 0.420 (0.00 to 1.44) | 0.280 (0.00 to 1.20) |
| Criteria 1, Grade M and Not Improved | 1.430 (0.25 to 2.54) | 1.520 (0.14 to 2.64) |
| Criteria 2, Grade N and Improved | 1.000 (0.00 to 2.00) | 0.640 (0.00 to 1.68) |
| Criteria 2, Grade N and Not Improved | 1.460 (0.60 to 2.82) | 1.695 (0.48 to 3.67) |
| Criteria 2, Grade M and Improved | 0.890 (0.00 to 2.14) | 0.710 (0.00 to 2.04) |
| Criteria 2, Grade M and Not Improved | 1.645 (0.44 to 2.54) | 1.790 (0.43 to 2.64) |
Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, higher score indicates greater severity. The percentage was calculated in each subgroup of the response (improved or not improved) in the participants who had a medication history of any of acid suppressants. The acid suppressants include proton pump inhibitors \[PPIs\], histamine H2-receptor antagonists \[H2RAs\], or other agents \[anticholinergics or anti-gastrin drugs\].
| percentage of days | Placebo | TAK-438 10 mg |
|---|---|---|
| Improved | 61.30 (0.0 to 100.0) | 71.40 (0.0 to 100.0) |
| Not Improved | 49.30 (0.0 to 100.0) | 80.80 (39.3 to 100.0) |
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Cumulative improvement rate calculated in each subgroup of the response (improved or not improved) in participants who had medication history of any of acid suppressants. Acid suppressants include proton pump inhibitors \[PPIs\], histamine H2-receptor antagonists \[H2RAs\], or other agents \[anticholinergics or anti-gastrin drugs\]. Cumulative data collected between Day 0 and Day 23 and is reported for following time points: Days 0, 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 and 23. Data not collected were shown as NA=Not Applicable.
| percentage of participants | Placebo | TAK-438 10 mg |
|---|---|---|
| Day 0 | 0.0 | 0.0 |
| Day 1 | 13.3 | 25.0 |
| Day 2 | 15.7 | 26.2 |
| Day 4 | 18.1 | NA |
| Day 5 | 20.5 | NA |
| Day 6 | 21.7 | 27.3 |
| Day 7 | NA | 28.5 |
| Day 8 | 22.9 | 29.6 |
| Day 9 | 25.3 | NA |
| Day 10 | NA | 30.8 |
| Day 11 | NA | 35.4 |
| Day 12 | 26.5 | NA |
| Day 13 | NA | 41.2 |
| Day 14 | 28.9 | 42.3 |
| Day 15 | 30.1 | 43.5 |
| Day 16 | 31.3 | NA |
| Day 17 | 32.6 | NA |
| Day 18 | 33.8 | 46.9 |
| Day 19 | 35.0 | NA |
| Day 20 | 36.3 | 49.4 |
| Day 21 | NA | 50.8 |
| Day 22 | 41.6 | 54.5 |
| Day 23 | 48.9 | 61.0 |
Participants recorded presence and severity (Without symptom \[No symptom:0, No hindrance to daily activities:1\], With symptom \[Mild:2, Moderate:3, Severe:4\]) of heartburn in participant diary. Score range was 0-4, higher score indicates greater severity. Cumulative rate of improvement calculated as percentage of participants who experienced symptom improvement. Cumulative improvement rate calculated in each subgroup of the response (improved or not improved) in participants who had medication history of any of acid suppressants. Acid suppressants include proton pump inhibitors \[PPIs\], histamine H2-receptor antagonists \[H2RAs\], or other agents \[anticholinergics or anti-gastrin drugs\]. Cumulative data was collected between Day 0 and Day 23 and is reported for following time points: Days 0, 1, 5, 9, 16, 19, and 20. Data not collected were shown as NA=Not Applicable.
| percentage of participants | Placebo | TAK-438 10 mg |
|---|---|---|
| Day 0 | 0.0 | 0.0 |
| Day 1 | 25.0 | 40.0 |
| Day 5 | NA | 60.0 |
| Day 9 | NA | 80.0 |
| Day 16 | 37.5 | NA |
| Day 19 | NA | 100.0 |
| Day 20 | 50.0 | NA |
Heartburn symptoms were collected by participant diaries. Participants recorded the presence and severity (Without symptom \[No symptom: 0, No hindrance to daily activities: 1\], With symptom \[Mild: 2, Moderate: 3, Severe: 4\]) of heartburn in a daily participant diary. The score range was 0-4, with the higher scores reflecting the greater severity. The mean severity of heartburn was calculated in each subgroup of the response (improved or not improved) in the participants who had a medication history of any of acid suppressants. The acid suppressants include proton pump inhibitors \[PPIs\], histamine H2-receptor antagonists \[H2RAs\], or other agents \[anticholinergics or anti-gastrin drugs\].
| score on a scale | Placebo | TAK-438 10 mg |
|---|---|---|
| Improved | 1.150 (0.00 to 2.82) | 1.040 (0.00 to 3.67) |
| Not Improved | 1.280 (0.00 to 2.00) | 1.030 (0.18 to 1.68) |
Collected over Up to Week 4. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/245 (0%) | 1/245 (0.4%) | 12/245 (4.9%) |
| TAK-438 10 mg | 0/238 (0%) | 0/238 (0%) | 10/238 (4.2%) |
| Event | Placebo | TAK-438 10 mg |
|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 1/245 | 0/238 |
| Event | Placebo | TAK-438 10 mg |
|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 12/245 | 10/238 |
Randomized Set included all participants who were randomized in the study.
| Age, Continuous(years) | Placebo | TAK-438 10 mg | Total |
|---|---|---|---|
| Mean | 51.8 ± 15.38 | 52.8 ± 14.37 | 52.3 ± 14.88 |
| Sex: Female, Male(Participants) | Placebo | TAK-438 10 mg | Total |
|---|---|---|---|
| Female | 140 | 161 | 301 |
| Male | 105 | 78 | 183 |
| Race and Ethnicity Not Collected(Participants) | Placebo | TAK-438 10 mg | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Placebo | TAK-438 10 mg | Total |
|---|---|---|---|
| Japan | 245 | 239 | 484 |
| Height(cm) | Placebo | TAK-438 10 mg | Total |
|---|---|---|---|
| Mean | 161.7 ± 8.62 | 160.5 ± 9.29 | 161.1 ± 8.97 |
| Weight(kg) | Placebo | TAK-438 10 mg | Total |
|---|---|---|---|
| Mean | 59.6 ± 12.04 | 58.7 ± 11.15 | 59.2 ± 11.61 |
| Body Mass Index (BMI)(kg/m^2) | Placebo | TAK-438 10 mg | Total |
|---|---|---|---|
| Mean | 22.67 ± 3.431 | 22.71 ± 3.375 | 22.69 ± 3.400 |
| Smoking Classification(Participants) | Placebo | TAK-438 10 mg | Total |
|---|---|---|---|
| Never Smoked | 124 | 128 | 252 |
| Current Smoker | 52 | 44 | 96 |
| Ex-smoker | 69 | 67 | 136 |
33 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Nov 2016 to primary completion in Feb 2018, 15 months.
Results were first posted in Aug 2019, 1 year 5 months after primary completion.
Of 21 phase 3 interventional studies under Gastroesophageal Reflux, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 49. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vonoprazan